One of the biggest bugbears of the contemporary pharmaceutical industry is the spectre of generic competition. All that time and money invested in research and development, protected so briefly, ...
Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could not have ...
How LIFO and FIFO accounting methods impact a company's inventory outlook Carla Tardi is a technical editor and digital content producer with 25+ years of experience at top-tier investment banks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results